Table 2.
Cytolytic activities (% specific lysis) of UBMC, PBMC, and YT2C2-PR cells against cytotrophoblasts and K562 transfectants
| Target cells* | Effector cells†
|
||||
|---|---|---|---|---|---|
| UBMC 122 | UBMC 138 | PBMC 583 | PBMC 770 | YT2C2-PR | |
| T122 + IgG2a | 2 | 5 | 10 | 0 | 0 |
| T122 + W6/32 | 15 | 17 | 34 | 17 | 0 |
| T138 + IgG2a | 7 | 8 | 0 | ND | 0 |
| T138 + W6/32 | 24 | 17 | 17 | ND | 0 |
| K562-pRc/RSV‡ | 12 | 20 | 22 | 24 | 27 |
| K562-HLA-G1 + IgG2a | 0 | 5 | 4 | 3 | 1 |
| K562-HLA-G1 + W6/32 | 9 | 14 | 16 | 24 | 2 |
Results are expressed as the percentage of specific lysis recorded in a 4-hr 51Cr-release assay. ND, not determined.
K562 transfected with either the vector alone (K562-pRc/RSV) or with HLA-G1 (K562-HLA-G1) were used as targets in addition to the Percoll gradient-purified cytotrophoblasts T122 and T138. Target cells were incubated either with the W6/32 mAb (bold characters) or the IgG2a isotype-matched control mAb at 10 μg/ml.
UBMC from mothers 122 and 138, PBMC from donors 583 and 770, and the YT2C2-PR clone were used as effector cells at a 25:1 E/T ratio.
Identical results were obtained with K562-pRc/RSV cells treated with either the IgG2a mAb or the W6/32 mAb.